Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALZN

Alzamend Neuro Inc

Nov 28 • 03:02PM ET

1.02

Dollar change +0.02
Percentage change 2.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.36	Insider Own	49.55%	Shs Outstand	6.46M	Perf Week	-26.26%
Market Cap	6.63M	Forward P/E	-	EPS next Y	-2.62	Insider Trans	1.68%	Shs Float	3.26M	Perf Month	-60.32%
Income	-15.37M	PEG	-	EPS next Q	-0.68	Inst Own	6.46%	Short Float / Ratio	1.20% / 0.37	Perf Quarter	-75.58%
Sales	0.00M	P/S	-	EPS this Y	-13.33%	Inst Trans	-	Short Interest	0.04M	Perf Half Y	-89.33%
Book/sh	-0.02	P/B	-	EPS next Y	-2.94%	ROA	-207.15%	Target Price	56.25	Perf Year	-94.44%
Cash/sh	0.26	P/C	3.90	EPS next 5Y	-	ROE	-277.69%	52W Range	0.96 - 18.60	Perf YTD	-87.90%
Dividend	-	P/FCF	-	EPS past 5Y	-69.45%	ROI	-	52W High	-94.49%	Beta	-0.19
Dividend %	-	Quick Ratio	0.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.74%	ATR	0.24
Employees	4	Current Ratio	0.88	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	27.22	Volatility	22.55% 15.95%
Optionable	No	Debt/Eq	-	EPS Q/Q	-15.02%	Profit Margin	-	Rel Volume	0.88	Prev Close	1.00
Shortable	Yes	LT Debt/Eq	-	Earnings	Jul 27 AMC	Payout	-	Avg Volume	104.70K	Price	1.02
Recom	1.00	SMA20	-31.12%	SMA50	-59.17%	SMA200	-83.34%	Volume	79,834	Change	2.50%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy	$8

Nov-20-23 08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Business Wire) -17.75%
Nov-16-23 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Nov-13-23 08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire) -6.85%
Oct-30-23 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire) -24.62%
Oct-23-23 09:31AM	EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder (Benzinga)
08:00AM	Loading…
08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire)
Oct-02-23 09:30AM	EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder (Benzinga) -8.48%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Sep-22-23 08:00AM	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Business Wire)
Aug-30-23 09:30AM	EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Jun-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study (Benzinga)
08:00AM	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Business Wire)
Jun-13-23 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Groups Virtual Healthcare Conference (Business Wire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) +10.30%
12:38PM	Loading…
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
Apr-04-23 06:30AM	Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Apr-03-23 09:35AM	KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) +15.29%
09:34AM	EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine (Benzinga)
08:50AM	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Mar-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial (Benzinga)
08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-17-23 07:09AM	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully (Simply Wall St.) -12.36%
Mar-16-23 08:00AM	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Business Wire)
Jan-26-23 08:00AM	Alzamend Neuro to Present at Sequire Biotechnology Conference (Business Wire) +9.48%
Jan-04-23 08:00AM	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Business Wire)
Dec-28-22 08:00AM	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) -11.31%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia (Benzinga)
Dec-13-22 03:52PM	10 Biotech Stocks With The Biggest Upside (Insider Monkey)
Nov-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. (ACCESSWIRE) +10.62%
08:00AM	Loading…
Nov-15-22 08:00AM	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Business Wire)
Oct-31-22 08:00AM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Oct-11-22 10:03AM	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies (Simply Wall St.) -11.19%
Oct-05-22 12:45PM	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial (Benzinga) +7.25%
08:00AM	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimers Subjects (Business Wire)
Sep-29-22 12:29PM	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Sep-22-22 08:00AM	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Business Wire) -7.63%
Aug-25-22 07:13AM	We Think Alzamend Neuro (NASDAQ:ALZN) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jul-18-22 10:42AM	Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate (Benzinga)
08:00AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire)
Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
Jun-03-22 08:00AM	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational (Business Wire)
May-17-22 08:00AM	Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire) +7.25%
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love (Insider Monkey) -6.74%
May-05-22 08:00AM	Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
May-04-22 06:25AM	What Kind Of Investors Own Most Of Alzamend Neuro, Inc. (NASDAQ:ALZN)? (Simply Wall St.)
Apr-28-22 06:30AM	BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
06:30AM	Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Apr-11-22 08:00AM	Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimers (Business Wire) -6.25%
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Apr-04-22 08:00AM	Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board (Business Wire)
Mar-28-22 08:00AM	Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-18-22 06:31AM	We're Hopeful That Alzamend Neuro (NASDAQ:ALZN) Will Use Its Cash Wisely (Simply Wall St.) +9.71%
Jan-13-22 04:00AM	ALZN: Coordinated Offensive on Alzheimers Disease (Zacks Small Cap Research)
Dec-17-21 09:54AM	Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate (Benzinga)
09:00AM	Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Dec-14-21 06:35PM	Why Alzamend Neuro Stock Soared Today (Motley Fool) +28.33%
11:18AM	MIND Stock: The U.S. Navy Deal That Has Mind Technology Shares Surging Today (InvestorPlace)
09:29AM	ALZN Stock Alert: What Is Going on With Alzamend Neuro Today? (InvestorPlace)
Nov-30-21 08:30AM	Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimers (Business Wire)
Nov-11-21 07:17AM	28 Stocks Moving in Thursday's Pre-Market Session (Benzinga) +11.63%
Oct-01-21 09:24AM	Company News for Oct 1, 2021 (Zacks) -6.49%
04:44AM	51 Biggest Movers From Yesterday (Benzinga)
Sep-30-21 01:45PM	See Why Alzamend Neuro Stock Is Rallying On Thursday (Benzinga) +35.09%
12:09PM	36 Stocks Moving In Thursday's Mid-Day Session (Benzinga)
11:54AM	Why Alzamend Neuro Shares Are Surging Higher Today (Benzinga)
10:11AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients Immunological System to Combat Alzheimers Disease (Business Wire)
Sep-16-21 06:09AM	ALZN: An Elemental Approach to Alzheimers Disease (Zacks Small Cap Research)
Sep-15-21 06:29AM	Could The Alzamend Neuro, Inc. (NASDAQ:ALZN) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Sep-13-21 06:30AM	Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimers Disease (Business Wire) -5.76%
Aug-17-21 10:59AM	Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate (Benzinga) -5.71%
08:00AM	Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimers Disease in September 2021 (Business Wire)
Aug-04-21 06:30AM	Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimers Pursuant to the Securities Purchase Agreement with Digital Power Lending (Business Wire)
Jul-30-21 06:30AM	Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients Immunological System to Combat Alzheimers (Business Wire) -5.04%
Jul-28-21 03:07PM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimers Disease (Business Wire) +18.10%
Jul-26-21 04:03PM	Why Alzamend Neuro Stock Fell More Than 14% Today (Motley Fool) -14.31%
Jul-23-21 12:44PM	Here's Why Alzamend Neuro Stock Is Shooting Higher Today (Motley Fool)
06:30AM	Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimers Disease (Business Wire)
Jul-12-21 06:00AM	Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today (Business Wire)
Jul-01-21 06:45AM	Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimers Disease (Business Wire) -12.13%
06:30AM	Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimers Disease (Business Wire)
Jun-28-21 03:59PM	Why Alzamend Neuro Stock Popped Today (Motley Fool) +11.63%
Jun-17-21 04:30PM	Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriters Over-allotment Option for Gross Proceeds of $14.4 Million (Business Wire)

Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Katzoff David J	Chief Financial Officer	Sep 26	Buy	0.19	53,000	10,234	81,000	Sep 26 06:01 PM
AULT MILTON C III	10% Owner	May 24	Buy	0.59	18,000	10,705	383,000	May 26 09:30 PM
Jackman Stephan	Chief Executive Officer	Apr 28	Buy	0.54	37,000	19,998	45,500	May 02 04:30 PM
McGrath Lynne Fahey	Director	Mar 22	Buy	0.43	10,000	4,350	10,000	Mar 23 04:30 PM
AULT MILTON C III	10% Owner	Mar 17	Buy	0.43	5,000	2,149	11,060,001	Mar 20 04:30 PM
AULT MILTON C III	10% Owner	Mar 16	Buy	0.50	4,000	2,006	11,055,001	Mar 20 04:30 PM
Horne William B.	Director	Feb 24	Option Exercise	0.00	500,000	2,000	1,000,000	Feb 28 04:30 PM
AULT MILTON C III	10% Owner	Feb 15	Buy	0.60	1,000	597	11,051,001	Feb 17 09:55 PM
AULT MILTON C III	10% Owner	Dec 28	Buy	0.56	3,100	1,745	11,050,001	Dec 29 06:00 AM
AULT MILTON C III	10% Owner	Dec 27	Buy	0.59	900	532	11,046,901	Dec 29 06:00 AM
AULT MILTON C III	10% Owner	Dec 21	Buy	0.81	5,000	4,049	11,046,001	Dec 23 04:30 PM
AULT MILTON C III	10% Owner	Dec 19	Buy	0.82	23,000	18,813	11,041,001	Dec 20 04:30 PM
AULT MILTON C III	10% Owner	Dec 16	Buy	0.90	20,000	17,960	345,000	Dec 20 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALZN

Alzamend Neuro Inc

Upgrade your FINVIZ experience